Lymphohistiocytic anaplastic large cell lymphoma stage I: Long-term survival after resection alone

Pediatric Hematology and Oncology

Volumn 17, Issue 3, 2000, Pages 261-268

  Kedar, Amos ^a   Braylan, Raul C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Ki 1 lymphoma; Lymphadenopathy; Lymphohistiocytic anaplastic large cell lymphoma; NPM ALK fusion protein

Indexed keywords

CD30 ANTIGEN;

ADOLESCENT; ARTICLE; BIOPSY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0034073987     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800100276442     Document Type: Article

References (16)

1. +/Ki-1 + with a high content of reactive histiocytes). Histopathology. 1990;16:383-391.
2. Pileri S, Sabattini E, Poggi S, Amini M, Falini B, Stein H. Lymphohistiocytic T-cell lymphoma. Histopathology. 1994;25:191-193.
3. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
4. Pileri SA, Pulford K, Mori S, et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol. 1997;150:1207-1211.
5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
6. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394-1404.
7. Greiner TC, Raffeld M, Lutz C, Dick F, Jaffe ES. Analysis of T cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products: correlation with tumor-specific sequences. Am J Pathol. 1995;146:46-55.
8. Guglielmi C, Amadori S, Anselmo AP, et al. Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP). Cancer Invest, 1987;5:159-169.
9. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602.
10. Lennert K, Feller AC. Histopathology of Non-Hodgkin's Lymphomas, 2d ed. New York: Springer; 1992: 256-258.
11. Ott G, Bastian BC, Katzenberger T, et al. A lymphohistiocytic variant of anaplastic large cell lymphoma with demonstration of the t(2;5)(p23;q35) chromosome translocation. Br J Haematol. 1998;100:187-190.
12. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
13. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153:875-886.
14. Pittaluga S, Wiodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997;151:343-351.
15. Weisenburger DD, Gordon BG, Vose JM, et al. Occurrence of the t(2;5) (p23;q35) in non-Hodgkin's lymphoma. Blood. 1996;87:3860-3868.
16. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913-3921.